JP2008521827A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521827A5
JP2008521827A5 JP2007543584A JP2007543584A JP2008521827A5 JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5 JP 2007543584 A JP2007543584 A JP 2007543584A JP 2007543584 A JP2007543584 A JP 2007543584A JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5
Authority
JP
Japan
Prior art keywords
agonist
receptor modulator
ethyl
phenyl
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007543584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043044 external-priority patent/WO2006058316A1/en
Publication of JP2008521827A publication Critical patent/JP2008521827A/ja
Publication of JP2008521827A5 publication Critical patent/JP2008521827A5/ja
Withdrawn legal-status Critical Current

Links

JP2007543584A 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン Withdrawn JP2008521827A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012040574A Division JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Division JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン

Publications (2)

Publication Number Publication Date
JP2008521827A JP2008521827A (ja) 2008-06-26
JP2008521827A5 true JP2008521827A5 (OSRAM) 2009-02-05

Family

ID=36046868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007543584A Withdrawn JP2008521827A (ja) 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Country Status (21)

Country Link
US (3) US20090275553A1 (OSRAM)
EP (3) EP2359821A1 (OSRAM)
JP (4) JP2008521827A (OSRAM)
KR (4) KR20130041385A (OSRAM)
CN (2) CN101068536B (OSRAM)
AU (1) AU2005309378B2 (OSRAM)
BR (1) BRPI0518674A2 (OSRAM)
CA (1) CA2589265A1 (OSRAM)
ES (1) ES2495690T3 (OSRAM)
IL (2) IL183134A0 (OSRAM)
MA (1) MA29034B1 (OSRAM)
MX (1) MX2007006373A (OSRAM)
NO (2) NO20072401L (OSRAM)
NZ (2) NZ590054A (OSRAM)
PL (1) PL1819326T3 (OSRAM)
PT (1) PT1819326E (OSRAM)
RU (2) RU2478384C2 (OSRAM)
SG (2) SG158096A1 (OSRAM)
TN (1) TNSN07209A1 (OSRAM)
WO (1) WO2006058316A1 (OSRAM)
ZA (1) ZA200703328B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509931A (ja) 2004-08-13 2008-04-03 プレーシス ファーマスーティカルズ インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
CA2620554C (en) * 2005-09-09 2013-12-17 Novartis Ag Treatment of autoimmune diseases
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101526835B1 (ko) 2007-05-04 2015-06-05 노파르티스 아게 Ｓ1ｐ 수용체 조절제의 용도
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
US9149459B2 (en) * 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
RU2523281C2 (ru) * 2008-08-18 2014-07-20 Новартис Аг Соединения для лечения периферических невропатий
CN103204794A (zh) * 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
RU2011129230A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
HRP20151190T1 (hr) * 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
US20120264719A1 (en) * 2009-09-29 2012-10-18 Craig Boulton Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
SI2885266T1 (sl) 2012-08-17 2020-10-30 Actelion Pharmaceuticals Ltd Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
WO1996006068A1 (en) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
CA2213989C (en) * 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1377593B1 (en) 2001-03-26 2005-12-28 Novartis AG 2-amino-propanol derivatives
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
ES2364816T3 (es) * 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
IL158384A0 (en) * 2001-06-08 2004-05-12 Novartis Ag Treatment or prophylaxis of insulin producing cell graft rejection
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
TWI335311B (en) * 2002-09-24 2011-01-01 Novartis Ag Organic compounds
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Similar Documents

Publication Publication Date Title
JP2008521827A5 (OSRAM)
RU2007124327A (ru) Курс лечения с использованием агониста рецептора s1p
US6436938B1 (en) Combination treatment for depression
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
RU2008108887A (ru) Жидкие составы
JP2004512328A5 (OSRAM)
JP2007507494A5 (OSRAM)
WO2006119958A2 (en) Use of flibanserin in the treatment of chronic pain
JP2019517587A5 (OSRAM)
JP2014505017A5 (OSRAM)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
HUT71222A (en) Pharmaceutical compositions for inhibiting pulmonary hypertenzive diseases containing 2-phenyl-3-aroyl-benzotiophene derivatives and process for their preparation
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
RU2009144846A (ru) Использование модулятора рецептора s1p
JP2004509857A5 (OSRAM)
JP2017512211A5 (OSRAM)
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
JP2003012557A (ja) 不安及びうつ病のための多剤併用治療
JP2007537287A5 (OSRAM)
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
JP2005511571A5 (OSRAM)
US20140336265A1 (en) Dosage Regimen of Diaryl Sulfide Derivatives
RU2009138032A (ru) Новое профилактическое и/или лекарственное средство против диабетической невропатии
JP2003523995A5 (OSRAM)